Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371137 · ClinicalTrials.gov registry record · Phase 3

A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia

A Phase 3 study, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
548
Enrollment target

NCT00371137: Completed Phase 3 study, sponsored by Jazz Pharmaceuticals.

NCT00371137 is a Phase 3 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 548 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371137, a Phase 3 study, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
548 participants
Enrollment target

Study Summary

The objective of this trial is to evaluate the safety and efficacy of Xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.

Primary Outcome

Percentage of pain VAS responders. Subjects with a \>= 30% reduction in pain VAS from baseline to endpoint (week 14) were considered responders; all other subjects were considered non-responders. Missing data were handled using BOCF (Baseline Observation Carried Forward). The pain VAS ranges from 0 (no pain) to 100 (worst imaginable pain). The pain VAS was collected morning, afternoon and evening. Baseline is the average value recorded for the measure during the week prior to the end-of-baseline

Interventions

  • DRUG Placebo
  • DRUG Xyrem®

Trial Details

FieldValue
Enrollment Target 548 participants
Start Date 2006-08
Est. Completion 2008-12
Phase Phase 3
Jazz Pharmaceuticals

128 total trials

What the finished NCT00371137 record still lists

NCT00371137 is an interventional study that assigns participants to a tested intervention. The registered 548 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (29% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00371137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00371137 about?

NCT00371137 is a clinical study titled "A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia". The objective of this trial is to evaluate the safety and efficacy of Xyrem® compared to placebo for the treatment of fibromyalgia in a randomized, double blind, placebo controlled, parallel group trial.

What is the current status of trial NCT00371137?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 548 participants. The study started on 2006-08. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00371137?

The interventions under investigation include: Placebo (DRUG), Xyrem® (DRUG).

Who is sponsoring clinical trial NCT00371137?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00371137's enrollment target sits among peer trials

548 689th of 2000 higher than 1,312 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01852448 · 550 participants

    Genetics of Insulin and Incretins in Cystic Fibrosis

  • NCT02995252 · 550 participants

    The HOPE Study: Characterizing Patients With Hepatitis B and C

  • NCT03474913 · 550 participants

    Upright MRI for Prostate Cancer Screening

  • NCT04761120 · 550 participants

    Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00371137, the US trial registry maintained by the National Library of Medicine. NCT00371137 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.